Arovella completes key manufacturing step to progress ALA‐101 to clinic
Arovella Therapeutics Ltd is pleased to announce its Good Manufacturing Practice (GMP)‐grade lentiviral vector for its lead product, ALA-101, has been successfully manufactured and passed quality release testing.
Arovella is developing ALA‐101 to treat CD19+ lymphomas and leukemias. A key requirement for the development of an iNKT cell therapy product is the establishment of the manufacturing process under GMP conditions. A critical component for this manufacturing is the GMP‐grade lentiviral vector, which carries the genetic material to program iNKT cells to target and eliminate cancer cells. The ALA‐101 vector is a 3rdgeneration lentiviral vector manufactured by Lentigen Technology, Inc, a world‐leading manufacturer of lentiviral vectors for cell and gene therapies.
Arovella’s CEO and MD, Dr. Michael Baker, commented: “This is a tremendous step forward for the ALA‐101 program and for Arovella. Producing GMP lentiviral vector is essential to developing ALA‐101 and we are delighted this major step was completed on schedule.”